Dr. Perl Discusses the Impact of the ELIANA Trial

Alexander E. Perl, MD
Published: Thursday, Mar 01, 2018



Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of the ELIANA trial in acute lymphoblastic leukemia (ALL).

In August 2017, the FDA approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. This approval was based off findings from the ELIANA trial of 63 patients who received a single dose of tisagenlecleucel. The overall remission rate was 82.5% (95% CI, 70.9-91.0) in treated subjects, and 40 patients (63%) had complete remission.

Perl says that the most exciting thing about the ELIANA trial is that this therapy can be done at any center that is properly equipped. The fact that the toxicities were uniform between the single-center data and the multi-center data was encouraging, Perl adds. There is a learning curve to CAR T-cell therapy, and physicians should refer their patients to centers that have experience administering it.
SELECTED
LANGUAGE


Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of the ELIANA trial in acute lymphoblastic leukemia (ALL).

In August 2017, the FDA approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. This approval was based off findings from the ELIANA trial of 63 patients who received a single dose of tisagenlecleucel. The overall remission rate was 82.5% (95% CI, 70.9-91.0) in treated subjects, and 40 patients (63%) had complete remission.

Perl says that the most exciting thing about the ELIANA trial is that this therapy can be done at any center that is properly equipped. The fact that the toxicities were uniform between the single-center data and the multi-center data was encouraging, Perl adds. There is a learning curve to CAR T-cell therapy, and physicians should refer their patients to centers that have experience administering it.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x